JP7520719B2 - 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター - Google Patents

生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター Download PDF

Info

Publication number
JP7520719B2
JP7520719B2 JP2020551263A JP2020551263A JP7520719B2 JP 7520719 B2 JP7520719 B2 JP 7520719B2 JP 2020551263 A JP2020551263 A JP 2020551263A JP 2020551263 A JP2020551263 A JP 2020551263A JP 7520719 B2 JP7520719 B2 JP 7520719B2
Authority
JP
Japan
Prior art keywords
rna
origin
seq
replication
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518150A (ja
JPWO2019183248A5 (https=
JP2021518150A5 (https=
Inventor
エー． ウィリアムズ，ジェームズ
Original Assignee
アルデブロン，エル．エル．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルデブロン，エル．エル．シー． filed Critical アルデブロン，エル．エル．シー．
Publication of JP2021518150A publication Critical patent/JP2021518150A/ja
Publication of JPWO2019183248A5 publication Critical patent/JPWO2019183248A5/ja
Publication of JP2021518150A5 publication Critical patent/JP2021518150A5/ja
Priority to JP2024110895A priority Critical patent/JP2024138410A/ja
Application granted granted Critical
Publication of JP7520719B2 publication Critical patent/JP7520719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
JP2020551263A 2018-03-21 2019-03-20 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター Active JP7520719B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024110895A JP2024138410A (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645892P 2018-03-21 2018-03-21
US62/645,892 2018-03-21
PCT/US2019/023209 WO2019183248A1 (en) 2018-03-21 2019-03-20 Viral and non-viral nanoplasmid vectors with improved production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024110895A Division JP2024138410A (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Publications (4)

Publication Number Publication Date
JP2021518150A JP2021518150A (ja) 2021-08-02
JPWO2019183248A5 JPWO2019183248A5 (https=) 2022-03-29
JP2021518150A5 JP2021518150A5 (https=) 2022-03-29
JP7520719B2 true JP7520719B2 (ja) 2024-07-23

Family

ID=66001381

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551263A Active JP7520719B2 (ja) 2018-03-21 2019-03-20 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
JP2024110895A Pending JP2024138410A (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024110895A Pending JP2024138410A (ja) 2018-03-21 2024-07-10 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター

Country Status (13)

Country Link
US (1) US12600984B2 (https=)
EP (2) EP3768846B1 (https=)
JP (2) JP7520719B2 (https=)
KR (1) KR20210016330A (https=)
CN (2) CN112154208B (https=)
AU (2) AU2019240068B2 (https=)
CA (1) CA3093346A1 (https=)
DK (1) DK3768846T5 (https=)
ES (1) ES2950736T3 (https=)
FI (1) FI3768846T3 (https=)
LT (1) LT3768846T (https=)
SG (1) SG11202009009UA (https=)
WO (1) WO2019183248A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183248A1 (en) * 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
GB2700048B (en) 2019-09-18 2026-03-04 Aldevron Llc synthetic dna vectors and method of use
JP7833134B2 (ja) * 2020-03-11 2026-03-19 アルデブロン，エル．エル．シー． 細菌宿主株
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CA3223292A1 (en) 2021-06-25 2022-12-29 Laura Van Lieshout Adeno-associated virus packaging systems
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
CN114045305B (zh) * 2021-10-15 2023-03-24 深圳市深研生物科技有限公司 多转座子系统
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
US20250354159A1 (en) * 2022-06-13 2025-11-20 Nanjing GenScript Biotech Co., Ltd. Wild-type-mutant pi protein switching expression system capable of increasing efficiency of preparing screening-tag-free plasmid
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
CN117305339B (zh) * 2023-11-30 2024-02-06 苏州左旋星生物科技有限公司 优化大肠杆菌基因编辑的载体及其应用
WO2025160245A1 (en) 2024-01-25 2025-07-31 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2025231315A2 (en) 2024-05-03 2025-11-06 Aldevron, L.L.C. Bacterial host strains
WO2026076187A1 (en) * 2024-10-03 2026-04-09 Aldevron, L.L.C. Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013602A1 (fr) 2000-08-16 2002-02-21 Kansai Technology Licensing Organization Co., Ltd. Mammifere transgenique non humain et procede de realisation de ce dernier, modele de maladie animale et procede de clarification de la fonction genique
US20040072326A1 (en) 2000-08-30 2004-04-15 Alfonso Cayota Guzicovsky Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
WO2005003342A1 (ja) 2003-07-08 2005-01-13 Japan Science And Technology Agency メチル化を利用したトランスジェニック生物を作製する方法およびシステム
WO2007004642A1 (ja) 2005-07-05 2007-01-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 改変トランスポゾンベクター及びその利用方法
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
JP2016521553A (ja) 2013-06-06 2016-07-25 ノバルティス アーゲー インフルエンザウイルス再集合

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04197185A (ja) * 1990-11-28 1992-07-16 Mitsui Toatsu Chem Inc 酵母発現ベクター及びこれを用いた誘導的発現
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
FR2821855B1 (fr) 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
CA2794446C (en) * 2001-04-04 2015-09-08 Genencor International, Inc. Uncoupled productive and catabolic host cell pathways
US20060088837A1 (en) * 2002-04-26 2006-04-27 Kazunari Taira Expression system for stem-loop rna molecule having rnai effect
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
MX2007001889A (es) 2004-08-19 2007-05-09 Nature Technology Corp Proceso para la fermentacion de adn de plasmido.
CA2577519A1 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
TWI311152B (en) 2004-09-17 2009-06-21 Boehringer Ingelheim Rcv Gmbh & Co K Host-vector system for antibiotic-free cole1 plasmid propagation
US9018012B2 (en) 2005-01-20 2015-04-28 Nature Technology Corporation Vectors and methods for genetic immunization
US9017966B2 (en) 2007-05-23 2015-04-28 Nature Technology Corporation E. coli plasmid DNA production
EP2152889B1 (en) * 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
ES2651911T3 (es) * 2007-08-14 2018-01-30 Commonwealth Scientific And Industrial Research Organisation Métodos mejorados de silenciamiento génico
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
US9012226B2 (en) 2009-03-13 2015-04-21 Nature Technology Corporation Bacterial strains with improved plasmid stability
US9506082B2 (en) 2010-04-12 2016-11-29 Nature Technology Corporation Eukaryotic expression vectors resistant to transgene silencing
EP2788483B1 (en) * 2011-12-07 2018-06-27 Glenmark Pharmaceuticals S.A. Expression cassette
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
US11230720B2 (en) 2015-10-14 2022-01-25 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2019183248A1 (en) 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013602A1 (fr) 2000-08-16 2002-02-21 Kansai Technology Licensing Organization Co., Ltd. Mammifere transgenique non humain et procede de realisation de ce dernier, modele de maladie animale et procede de clarification de la fonction genique
US20040072326A1 (en) 2000-08-30 2004-04-15 Alfonso Cayota Guzicovsky Methods for preparing human thrombopoietin polypeptides by mammalian cell cultures
WO2005003342A1 (ja) 2003-07-08 2005-01-13 Japan Science And Technology Agency メチル化を利用したトランスジェニック生物を作製する方法およびシステム
WO2007004642A1 (ja) 2005-07-05 2007-01-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 改変トランスポゾンベクター及びその利用方法
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
JP2016521553A (ja) 2013-06-06 2016-07-25 ノバルティス アーゲー インフルエンザウイルス再集合

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Carnes A et al，Production of a Nanoplasmid with a large gene insert using the HyperGRO fermentation process，Engineering Conferences International ECI Digital Archives VACCINE TECHNOLOGY VI，2016年
Lu J et al.，A 5 Noncoding Exon Containing Engineered Intron Enhances Transgene Expression from Recombinant AAV Vectors in vivo，HUMAN GENE THERAPY，2016年，28(1)，p125-134, Supplemetary FigureS2

Also Published As

Publication number Publication date
DK3768846T5 (da) 2024-08-19
JP2021518150A (ja) 2021-08-02
US12600984B2 (en) 2026-04-14
EP4151735A1 (en) 2023-03-22
EP3768846B1 (en) 2023-06-21
DK3768846T3 (da) 2023-07-24
LT3768846T (lt) 2023-08-10
FI3768846T3 (fi) 2023-06-30
CA3093346A1 (en) 2019-09-29
JP2024138410A (ja) 2024-10-08
ES2950736T3 (es) 2023-10-13
AU2019240068B2 (en) 2025-03-13
SG11202009009UA (en) 2020-10-29
CN112154208B (zh) 2025-04-15
CN112154208A (zh) 2020-12-29
AU2019240068A1 (en) 2020-10-01
US20210010021A1 (en) 2021-01-14
AU2025203312A1 (en) 2025-05-29
WO2019183248A1 (en) 2019-09-26
KR20210016330A (ko) 2021-02-15
CN120249340A (zh) 2025-07-04
EP3768846A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
JP7520719B2 (ja) 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
US12215335B2 (en) Non-integrating DNA vectors for the genetic modification of cells
US10167478B2 (en) Replicative minicircle vectors with improved expression
JP7833134B2 (ja) 細菌宿主株
EP2890404A1 (en) Dna plasmids with improved expression
WO2019057774A1 (en) NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
WO2025160245A1 (en) Viral and non-viral nanoplasmid vectors with improved production
HK40129088A (zh) 产生改进的病毒和非病毒纳米质粒载体
WO2025231315A2 (en) Bacterial host strains
HK40031637B (en) Non-integrating dna vectors for the genetic modification of cells
HK40031637A (en) Non-integrating dna vectors for the genetic modification of cells

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240710

R150 Certificate of patent or registration of utility model

Ref document number: 7520719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150